David S. Burgess

Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test

Roger L. White, David S. Burgess, Madhavi Manduru et al. · Antimicrobial Agents and Chemotherapy · 1996 · 700 citations · Full text

Life Sciences, Microbiology, Bacteriology +12

Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients

Glenn Deng, Michael Herrler, David S. Burgess et al. · Breast Cancer Research · 2008 · 179 citations · Full text

Medicine, Cell Biology, Oncology +17

Impact of Guideline-Concordant Empiric Antibiotic Therapy in Community-Acquired Pneumonia

Christopher R. Frei, Marcos I. Restrepo, Eric M. Mortensen et al. · The American Journal of Medicine · 2006 · 135 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime

W. Cliff Rutter, Jessica N. Cox, Craig A. Martin et al. · Antimicrobial Agents and Chemotherapy · 2016 · 116 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic–pharmacodynamic models with Monte Carlo simulation

Christopher R. Frei, Nathan P. Wiederhold, David S. Burgess · Journal of Antimicrobial Chemotherapy · 2008 · 103 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16